Treatment of patients with multiple sclerosis: a review of guidelines
CADTH
Record ID 32014000198
English
Authors' recommendations:
Limited evidence-based guidelines are available for the treatment of multiple sclerosis, and the stopping or switching of treatment. The available evidence has suggested plasmapheresis as an adjunctive or alternative treatment for MS, corticosteroids for the treatment of relapse, and natalizumab in cases of failure on other drugs or intolerance.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.cadth.ca/media/pdf/htis/march-2013/RC0436%20MS%20Guidelines%20final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Multiple Sclerosis
- Practice Guidelines as Topic
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.